©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273
Table 3 Breakdown of Harvey-Bradshaw Index scores at each data point classified based upon severity of disease, n (%)
| Baseline | 3 months | 6 months | 9 months | |
| Remission (< 5) | 20 (39.2) | 33 (70.2) | 25 (78.1) | 18 (94.7) |
| Mild disease (5-7) | 14 (27.5) | 9 (19.2) | 6 (18.8) | 1 (5.3) |
| Moderate disease (8-16) | 12 (23.5) | 3 (6.4) | 1 (3.1) | 0 |
| Severe disease (> 16) | 4 (7.8) | 3 (6.4) | 0 | 0 |
- Citation: Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A. Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center. World J Gastrointest Pharmacol Ther 2025; 16(4): 110273
- URL: https://www.wjgnet.com/2150-5349/full/v16/i4/110273.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i4.110273